Julio D Duarte

List of Publications by Year
in descending order

29 papers	876 citations	623574 14 h-index	501076 28 g-index
29 all docs	29 docs citations	29 times ranked	1337 citing authors

#	Article	IF	Citations
1	Multisite Investigation of Outcomes WithÂImplementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 181-191.	1.1	213
2	Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Review of Cardiovascular Therapy, 2010, 8, 793-802.	0.6	175
3	Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotypeâ€Guided Antiplatelet Therapy. Clinical Pharmacology and Therapeutics, 2018, 104, 664-674.	2.3	94
4	Pharmacogenetics to guide cardiovascular drug therapy. Nature Reviews Cardiology, 2021, 18, 649-665.	6.1	49
5	Implementation of inpatient models of pharmacogenetics programs. American Journal of Health-System Pharmacy, 2016, 73, 1944-1954.	0.5	34
6	Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. Genetics in Medicine, 2021, 23, 2335-2341.	1.1	32
7	Association of Genetic Variants With Warfarin-Associated Bleeding Among Patients of African Descent. JAMA - Journal of the American Medical Association, 2018, 320, 1670.	3.8	25
8	Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. Pharmacogenomics Journal, 2020, 20, 724-735.	0.9	25
9	Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotypeâ€Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. Clinical Pharmacology and Therapeutics, 2021, 109, 705-715.	2.3	25
10	County-level longitudinal clustering of COVID-19 mortality to incidence ratio in the United States. Scientific Reports, 2021, 11, 3088.	1.6	25
11	CYP2C19 Genotypeâ€Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings. Journal of the American Heart Association, 2022, 11, e024159.	1.6	24
12	IL-18 mediates sickle cell cardiomyopathy and ventricular arrhythmias. Blood, 2021, 137, 1208-1218.	0.6	22
13	Epigenetics Primer: Why the Clinician Should Care About Epigenetics. Pharmacotherapy, 2013, 33, 1362-1368.	1.2	16
14	Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide. Pharmacogenetics and Genomics, 2010, 20, 516-519.	0.7	15
15	Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure. Journal of Cardiac Failure, 2016, 22, 692-699.	0.7	13
16	Therapeutic Challenges and Emerging Treatment Targets for Pulmonary Hypertension in Left Heart Disease. Journal of the American Heart Association, 2021, 10, e020633.	1.6	13
17	CYP2D6 Protein Level Is the Major Contributor to Interindividual Variability in CYP2D6â€Mediated Drug Metabolism in Healthy Human Liver Tissue. Clinical Pharmacology and Therapeutics, 2018, 104, 974-982.	2.3	12
18	Genome-Wide Analysis Identifies IL-18 and FUCA2 as Novel Genes Associated with Diastolic Function in African Americans with Sickle Cell Disease. PLoS ONE, 2016, 11, e0163013.	1.1	11

#	Article	IF	Citations
19	Transcriptome-wide analysis associates ID2 expression with combined pre- and post-capillary pulmonary hypertension. Scientific Reports, 2019, 9, 19572.	1.6	11
20	Endothelial nitric oxide synthase genotype is associated with pulmonary hypertension severity in left heart failure patients. Pulmonary Circulation, 2018, 8, 1-8.	0.8	10
21	NR3C2 Genotype is Associated with Response to Spironolactone in Diastolic Heart Failure Patients from the Aldoâ€ÐHF Trial. Pharmacotherapy, 2021, , .	1.2	7
22	Patients with geographic barriers to health care access are prescribed a higher proportion of drugs with pharmacogenetic testing guidelines. Clinical and Translational Science, 2021, 14, 1841-1852.	1.5	6
23	Determinants of Cytochrome P450 2D6 <scp>mRNA</scp> Levels in Healthy Human Liver Tissue. Clinical and Translational Science, 2019, 12, 416-423.	1.5	5
24	Genes affecting warfarin responseâ€"interactive or additive?. Journal of Clinical Pharmacology, 2015, 55, 258-260.	1.0	3
25	Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking Î²-blockers. Pharmacogenomics Journal, 2022, 22, 62-68.	0.9	3
26	Î²1â€receptor polymorphisms and junctional ectopic tachycardia in children after cardiac surgery. Clinical and Translational Science, 2022, 15, 619-625.	1.5	3
27	Beta-blocker Dose Stratifies Mortality Risk in a Racially Diverse Heart Failure Population. Journal of Cardiovascular Pharmacology, 2019, 75, 1.	0.8	2
28	Cox-sMBPLS: An Algorithm for Disease Survival Prediction and Multi-Omics Module Discovery Incorporating Cis-Regulatory Quantitative Effects. Frontiers in Genetics, 2021, 12, 701405.	1.1	2
29	Changing from mandatory to optional genotyping results in higher acceptance of pharmacist-guided warfarin dosing. Pharmacogenomics, 2022, 23, 85-95.	0.6	1